194 related articles for article (PubMed ID: 24309980)
21. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J; Lipton JH; Rea D; Digumarti R; Chuah C; Nanda N; Benichou AC; Craig AR; Michallet M; Nicolini FE; Kantarjian H;
Blood; 2012 Sep; 120(13):2573-80. PubMed ID: 22896000
[TBL] [Abstract][Full Text] [Related]
22. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.
Heiblig M; Sobh M; Nicolini FE
Leuk Res; 2014 Oct; 38(10):1145-53. PubMed ID: 24906663
[TBL] [Abstract][Full Text] [Related]
25. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
26. Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Visani G; Isidori A
Expert Opin Pharmacother; 2014 Jan; 15(1):1-3. PubMed ID: 24152096
[TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Quintás-Cardama A; Kantarjian H; Cortes J
Cancer; 2009 Dec; 115(23):5382-93. PubMed ID: 19739234
[TBL] [Abstract][Full Text] [Related]
28. Omacetaxine (Synribo) for CML.
Med Lett Drugs Ther; 2015 May; 57(1469):e80-1. PubMed ID: 26039555
[No Abstract] [Full Text] [Related]
29. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
30. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE; Khoury HJ; Akard L; Rea D; Kantarjian H; Baccarani M; Leonoudakis J; Craig A; Benichou AC; Cortes J
Haematologica; 2013 Jul; 98(7):e78-9. PubMed ID: 23753022
[No Abstract] [Full Text] [Related]
31. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.
Allan EK; Holyoake TL; Craig AR; Jørgensen HG
Leukemia; 2011 Jun; 25(6):985-94. PubMed ID: 21468038
[TBL] [Abstract][Full Text] [Related]
32. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü S; Wang J
J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
[TBL] [Abstract][Full Text] [Related]
34. Updated product label allows home administration of omacetaxine mepesuccinate.
Shen AQ; Munteanu M; Khoury HJ
Oncologist; 2014 Nov; 19(11):e14. PubMed ID: 25280490
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J; Mita A; Stephenson J; Mita MM; Sarantopoulos J; Padmanabhan-Iyer S; Nanda N; Gleich L; Benichou AC; Craig A
Cancer Chemother Pharmacol; 2013 Jan; 71(1):35-41. PubMed ID: 23053254
[TBL] [Abstract][Full Text] [Related]
36. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
37. A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected.
Winer ES; DeAngelo DJ
Oncol Ther; 2018 Jun; 6(1):9-20. PubMed ID: 32700137
[TBL] [Abstract][Full Text] [Related]
38. Omacetaxine: the FDA decision.
Berman E
Clin Adv Hematol Oncol; 2011 Jan; 9(1):57-8. PubMed ID: 21326148
[No Abstract] [Full Text] [Related]
39. Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Chen Y; Li S
Onco Targets Ther; 2014; 7():177-86. PubMed ID: 24516334
[TBL] [Abstract][Full Text] [Related]
40. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.
Wetzler M; Kantarjian HM; Nicolini FE; Lipton JH; Akard L; Baccarani M; Khoury HJ; Li E; Munteanu M; Cortes J
Blood Cancer J; 2015 Dec; 5(12):e376. PubMed ID: 26657200
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
